SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma reply to clarification sought by the exchange

23 Nov 2016 Evaluate

The Exchange had sought clarification from Aurobindo Pharma with respect to news appearing on CNBC TV18 on November 22, 2016 titled ‘Vietnam Government blacklists Aurobindo Pharma on quality issues.’ Aurobindo Pharma response is enclosed.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1388.30 -1.25 (-0.09%)
04-May-2026 10:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1826.85
Dr. Reddys Lab 1301.65
Cipla 1321.75
Zydus Lifesciences 896.95
Lupin 2332.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×